• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pres & Chief Operating Officer Stone Warren covered exercise/tax liability with 8,776 shares, decreasing direct ownership by 8% to 99,504 units (SEC Form 4)

    12/3/25 5:17:13 PM ET
    $NEO
    Precision Instruments
    Health Care
    Get the next $NEO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Stone Warren

    (Last) (First) (Middle)
    9490 NEOGENOMICS WAY

    (Street)
    FORT MYERS FL 33912

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NEOGENOMICS INC [ NEO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Pres & Chief Operating Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    12/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/01/2025 F 8,776(1) D $0 99,504 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $11.21 (2) 12/01/2029 Common Stock 166,113 166,113 D
    Stock Option (Right to Buy) $19.65 (3) 05/11/2030 Common Stock 53,969 53,969 D
    Performance Stock Unit $0 05/11/2026(4) (5) Common Stock 21,204 21,204 D
    Restricted Stock Unit $0 (6) (5) Common Stock 9,613 9,613 D
    Stock Option (Right to Buy) $16.45 (7) 02/23/2034 Common Stock 42,344 42,344 D
    Restricted Stock Unit $0 (8) (5) Common Stock 16,886 16,886 D
    Performance Stock Unit $0 02/23/2027(9) (5) Common Stock 25,330 25,330 D
    Stock Option (Right to Buy) $13.96 (10) 05/02/2034 Common Stock 29,976 29,976 D
    Restricted Stock Unit $0 (11) (5) Common Stock 17,908 17,908 D
    Performance Stock Unit $0 05/02/2027(12) (5) Common Stock 17,908 17,908 D
    Restricted Stock Unit $0 01/13/2026 (5) Common Stock 59,382 59,382 D
    Stock Option (Right to Buy) $13.05(13) (14) 02/21/2035 Common Stock 143,266 143,266 D
    Restricted Stock Unit $0 (15) (5) Common Stock 84,317 84,317 D
    Stock Option (Right to Buy) $10.44(16) (17) 04/01/2035 Common Stock 94,518 94,518 D
    Restricted Stock Unit $0 (18) (5) Common Stock 52,687 52,687 D
    Explanation of Responses:
    1. Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2025 vesting of restricted stock.
    2. On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date.
    3. On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date.
    4. On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
    5. Once vested, the shares of common stock are not subject to expiration.
    6. On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
    7. On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
    8. On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
    9. On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
    10. On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date.
    11. On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
    12. On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
    13. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
    14. On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President &Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
    15. On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone'spromotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grantdate.
    16. This stock option was granted as a premnium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
    17. On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
    18. On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.
    Remarks:
    /s/ Ali Olivo, Attorney-in-Fact 12/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEO

    DatePrice TargetRatingAnalyst
    7/30/2025Buy → Neutral
    BTIG Research
    7/29/2025Outperform → Mkt Perform
    William Blair
    5/15/2025Neutral
    Guggenheim
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    1/13/2025Buy → Hold
    The Benchmark Company
    12/10/2024$22.00Buy
    Jefferies
    5/1/2024$26.00Buy
    Craig Hallum
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    More analyst ratings

    $NEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

    NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court's August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics' favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics' motion for summary judgment and held that Natera's asserted patent claims are invalid for claiming ineligible subject

    12/15/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Present New ctDNA Research at SABCS 2025

    Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR® 1.0 assay for the detection of molecular residual disease (MRD) will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. NeoGenomics will present new data from the SURVIVE HERoes Phase III trial and the CLEVER study, both of which used RaDaR 1.0 circulating tumor DNA (ctDNA) testin

    12/10/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott covered exercise/tax liability with 11,938 shares, decreasing direct ownership by 6% to 176,394 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    12/9/25 4:16:26 PM ET
    $NEO
    Precision Instruments
    Health Care

    Pres & Chief Operating Officer Stone Warren covered exercise/tax liability with 8,776 shares, decreasing direct ownership by 8% to 99,504 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    12/3/25 5:17:13 PM ET
    $NEO
    Precision Instruments
    Health Care

    EVP, GC & Business Development Olivo Alicia C exercised 8,977 shares at a strike of $10.05 and sold $250,992 worth of shares (20,916 units at $12.00), decreasing direct ownership by 28% to 31,083 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    11/28/25 4:18:22 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    SEC Filings

    View All

    NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    12/30/25 7:07:40 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form 10-Q filed by NeoGenomics Inc.

    10-Q - NEOGENOMICS INC (0001077183) (Filer)

    10/28/25 4:05:09 PM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGENOMICS INC (0001077183) (Filer)

    10/28/25 7:09:29 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sherman Jeffrey Scott bought $112,322 worth of shares (20,000 units at $5.62), increasing direct ownership by 12% to 188,332 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:57 PM ET
    $NEO
    Precision Instruments
    Health Care

    Chief Executive Officer Zook Anthony P. bought $99,954 worth of shares (17,900 units at $5.58), increasing direct ownership by 89% to 38,066 units (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    8/6/25 4:07:25 PM ET
    $NEO
    Precision Instruments
    Health Care

    Director Kelly Michael Aaron bought $38,000 worth of shares (5,000 units at $7.60) (SEC Form 4)

    4 - NEOGENOMICS INC (0001077183) (Issuer)

    5/28/25 4:07:40 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NeoGenomics downgraded by BTIG Research

    BTIG Research downgraded NeoGenomics from Buy to Neutral

    7/30/25 7:31:39 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics downgraded by William Blair

    William Blair downgraded NeoGenomics from Outperform to Mkt Perform

    7/29/25 12:56:34 PM ET
    $NEO
    Precision Instruments
    Health Care

    Guggenheim initiated coverage on NeoGenomics

    Guggenheim initiated coverage of NeoGenomics with a rating of Neutral

    5/15/25 8:12:40 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Leadership Updates

    Live Leadership Updates

    View All

    NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. "Jack" Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully i

    12/30/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue a

    6/24/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

    Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

    3/18/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    11/14/24 1:28:29 PM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G filed by NeoGenomics Inc.

    SC 13G - NEOGENOMICS INC (0001077183) (Subject)

    2/14/24 10:04:34 AM ET
    $NEO
    Precision Instruments
    Health Care

    SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

    SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

    2/13/24 5:09:41 PM ET
    $NEO
    Precision Instruments
    Health Care

    $NEO
    Financials

    Live finance-specific insights

    View All

    NeoGenomics Reports Third Quarter 2025 Results

    Third quarter total revenue increased 12% YoY to $188 million Clinical revenue grew 18%, or 15% excluding the Pathline acquisition NGS revenue increased 24% YoY and now accounts for nearly one-third of clinical revenue Re-affirming full-year guidance for revenue, net loss and adjusted EBITDA NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended September 30, 2025. Third Quarter 2025 Highlights As Compared To Third Quarter 2024   Consolidated revenue increased 12% to a record $188 million, driven by Clinical revenue growth of 18%

    10/28/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

    NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domesti

    10/7/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics Reports Second Quarter 2025 Results

    Second Quarter Revenue Increased 10% to $181 million; Clinical Revenue Grew 16%, 13% excluding Pathline; Updates Full Year 2025 Guidance NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. Second Quarter 2025 Highlights As Compared To Second Quarter 2024   Consolidated revenue increased 10% to record $181 million   Net loss increased 142% to $45 million including $20 million of impairment charges   Adjusted EBITDA remained relatively flat at positive $11 million  

    7/29/25 7:05:00 AM ET
    $NEO
    Precision Instruments
    Health Care